研究单位：[1]Beijing InnoCare Pharma Tech Co., Ltd.[2]Tongji Hospital Wuhan, Hubei, China, 430030[3]Jiangsu Province Hospital Nanjing, Jiangsu, China, 210029[4]Jilin Cancer Hospital Chang Chun, Jilin, China, 130012[5]The First Hospital of Jilin University Changchun, Jilin, China, 130021[6]The second affiliated hospital of dalian medical university Dalian, Liaoning, China, 116044[7]Qilu Hosptial of Shandong University Jinan, Shandong, China, 250012[8]Shandong Provincial Hospital Jinan, Shandong, China, 250021[9]Xinhua hospital affiliated to medical college of Shanghai jiao tong university Shanghai, Shanghai, China, 200025[10]West China Hospital,Sichuan University Chengdu, Sichuan, China, 610041[11]The Chinese Academy of Medical Sciences Hematology Hospital Tianjin, Tianjin, China, 300020[12]Tianjin Medical University Cancer Institute and Hospital Tianjin, Tianjin, China, 300060[13]The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou, Zhejiang, China, 310052[14]Second affiliated hospital of medical college of zhejiang university Hangzhou, Zhejiang, China[15]Wuhan Union Hospital Wuhan, Hubei, China, 430022[16]Henan Tumor Hospital Zhengzhou, Henan, China, 450008[17]Henan Provincial People's Hospital Zhengzhou, Henan, China, 450003[18]The Fourth Hospital of Hebei Medical University Shijiazhuang, Hebei, China, 050011[19]Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China, 510060[20]Guangzhou First People's Hospital Guangzhou, Guangdong, China, 510180
研究目的：
The phase I/II clinical study is to investigate the safety, tolerability and efficacy of ICP-022 in R/R CLL/SLL patients.
